Savara Inc.

NasdaqGS SVRA

Savara Inc. Goodwill for the quarter ending September 30, 2024

Savara Inc. Goodwill is NA for the quarter ending September 30, 2024. Goodwill is the value attributed to intangible assets, such as brand reputation or customer relationships, acquired in a business combination.

Savara Inc. Goodwill for the quarter ending September 30, 2022 was USD 0.00, a 0.00% change year over year.
Savara Inc. Goodwill for the quarter ending September 30, 2021 was USD 0.00, a 0.00% change year over year.
Savara Inc. Goodwill for the quarter ending September 30, 2020 was USD 0.00, a -100.00% change year over year.

Key data

Date	Goodwill	Total Assets	Current Liabilities	Total Non-Current Liabilities

NasdaqGS: SVRA

Savara Inc.

CEO	Mr. Matthew Pauls J.D., M.B.A.
IPO Date	April 28, 2017
Location	United States
Headquarters	Building III
Employees	37
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Composite Materials Drones Pharmaceuticals Plastics Vaccines

Description

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Key trends

Past 5 years